Group Leader:
Georges Lacaud
I graduated as a biotechnology engineer from the European Biotechnology School of Strasbourg (ESBS) in Strasbourg, France. I obtained my PhD from the University Louis Pasteur of Strasbourg, France and then did a postdoctoral fellowship at the National Jewish Medical Center in Denver, Colorado, USA studying early lymphoid cell development in Prof. Gordon Keller’s lab. I next moved to the Mount Sinai School of Medicine in New York, NY, USA where I worked on early hematopoietic development. In 2003, I joined the Paterson Institute for Cancer Research as a junior group leader and I currently head the Stem Cell Biology group.
Postdoctoral Fellows:
Christophe Lancrin
Flor Perez-Campo
Cristina Ferreras
Michael Lie-A-Ling
Scientific Officer:
Catherine Gavin / Ting Zheng
Graduate Students:
Patrycja Sroczynska
Olga Tsoulaki
Monika Antkiewicz
Milena Mazan
Stem Cell Biology Group
The transcription factor AML1/RUNX1 is a frequent target of gene rearrangements and mutations in human acute myelogenous leukaemia (AML) and acute lymphoblastic leukaemia (ALL). Consistent with its implication in leukaemias, RUNX1 has also been shown to be critical for haematopoietic development. The MOZ gene is involved in three independent myeloid chromosomal translocations fusing MOZ to the partner genes CBP, P300 or TIF2. Our group studies the function of these two genes in haematopoietic development and maintenance with the aim to better understand how alterations of these functions lead to leukaemogenesis. We use complementary approaches such as in vitro differentiation of mouse embryonic stem (ES) cells and in vivo mouse models.
